## OMC: Omnicom Group Inc. - XLC: Communication Services

### Executive Summary

No thesis match: MRS_10 1.4% below STRENGTH zone (3.0-6.0%); PEG 16.28 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-7.5% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($76.05)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 4, Bearish: 0)

**1. Assessing Omnicom After Recent Media Wins and Data Driven Marketing Partnerships**
- Source: Simply Wall Street | 20251219T020905 | Bullish | Relevance: 100%
- Omnicom Group (NYSE: OMC) is considered undervalued based on a Discounted Cash Flow (DCF) analysis, which suggests a 50.4% discount to its estimated fair value of $164.52 per share compared to the current price around $81. The company's price-to-earnings ratio of 19.35x, while above the media industry average, is below that of its listed peers, indicating cautious market pricing. Recent media wins and data-driven marketing partnerships, alongside long-term shifts towards digital and AI-powered ad solutions, contribute to an improving sentiment around the stock.

**2. Oak Thistle LLC Takes $1.30 Million Position in Omnicom Group Inc. $OMC**
- Source: MarketBeat | 20251218T110938 | Somewhat-Bullish | Relevance: 100%
- Oak Thistle LLC recently acquired a new position in Omnicom Group Inc. (NYSE:OMC) by purchasing 15,890 shares valued at approximately $1.30 million during Q3. The company has an average "Hold" rating from analysts with a consensus price target of $92.57, and Omnicom also increased its quarterly dividend to $0.80 per share, resulting in a 3.9% yield. Several institutional investors have adjusted their holdings in Omnicom, reflecting varied confidence in the business services provider.

**3. Omnicom Group (OMC): Is the Recent Share Price Rebound Leaving the Stock Undervalued?**
- Source: Simply Wall Street | 20251218T001053 | Somewhat-Bullish | Relevance: 100%
- Omnicom Group has seen a recent share price rebound, with the stock up 13% in the past month. Despite this momentum, the company is still slightly negative year-to-date and is considered undervalued with a narrative fair value near $101.56 against its last close of $82.70. This undervaluation is supported by disciplined cost management, operational restructuring, and anticipated synergy targets, with potential risks from integration hurdles and AI-driven in-housing by clients.

**4. Omnicom Health merges DDB Health, The Purpose Group to create Remedy Edge**
- Source: Medical Marketing and Media | 20251217T220336 | Somewhat-Bullish | Relevance: 100%
- Omnicom Health has merged DDB Health and The Purpose Group to form a new full-service agency named Remedy Edge. This new entity will combine DDB Health’s HCP marketing expertise with The Purpose Group’s patient-centric knowledge. Remedy Edge will be led by Jennie Fischette, former CEO of DDB Health, and Michael Schreiber, former managing partner and chief creative officer of DDB Health.

**5. Should Value Investors Buy Omnicom Group (OMC) Stock?**
- Source: Yahoo Finance Singapore | 20251219T150848 | Bullish | Relevance: 100%
- Omnicom Group (OMC) is presented as a strong candidate for value investors, holding a Zacks Rank #2 (Buy) and a Value grade of A. The stock trades with an attractive P/E ratio of 8.41 and a P/CF ratio of 9.11, both significantly lower than its industry averages. These metrics suggest the stock is currently undervalued, making it an impressive value stock according to Zacks Investment Research.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-05 | UBS | $108 | $99 | +9% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-05 | UBS | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 13 ($0.00M) |
| Sells | 0 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 59.2% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 12.3% (-0.4%)
- Blackrock Inc.: 10.7% (+0.7%)
- State Street Corpora: 8.7% (+15.8%)
- JPMORGAN CHASE & CO: 8.4% (+160.9%)
- Massachusetts Financ: 3.9% (-5.5%)

### Key Risks

1. Valuation stretched: PEG 16.3x requires aggressive growth execution.
2. Elevated short interest (10.3%): bears positioning against stock.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 16.28 signals overvaluation risk, limited margin of safety. Forward P/E 8.2x attractive for 15% earnings growth. Quality metrics strong (ROE 27%). Analyst sentiment positive (1 raises, avg +9%). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $25.5B |
| Beta | 0.76 |
| 52W Range | $68.37 - $89.81 |
| Short Interest | 10.3% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 16.28 |
| Forward P/E | 8.2 |
| Current P/E | 9.5 |
| YoY Growth | 15.1% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from 8.9% to 1.4% (-7.5% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 1.6pp (needs >3.0% for momentum thesis). MRS_5 (-2.3%) diverging from MRS_10 - short-term weakness emerging. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (0.90), confirming momentum. OFD pattern: -MTH (Decline).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 1.38% (CS: 77) | Neutral |
| RSI_14 | 61.8 | Neutral |
| MACD Histogram | 0.90 | Bullish |
| vs SMA20 | 1.059x | Above |
| vs SMA50 | 1.061x | Above |
| vs SMA200 | 1.061x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $80.23
- **Stop Loss:** $76.05 (5.2% risk)
- **Target:** $84.41 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 287
- **Position Value:** $23,026.01
- **Portfolio %:** 23.03%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with improving risk appetite as VIX falls to 6th percentile and tech rally resumes on AI infrastructure demand. Fed pause expectations from cooling CPI data support equities, though elevated put/call ratio suggests cautious positioning. Focus on quality names in AI-exposed sectors.*

### Earnings

**Next:** 2026-02-10 (Est: $2.63)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.17 | $2.24 | +3.1% |
| 2025Q2 | $2.03 | $2.05 | +0.8% |
| 2025Q1 | $1.66 | $1.70 | +2.3% |
| 2024Q4 | $2.39 | $2.41 | +0.8% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_10*